These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18616803)

  • 1. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
    Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
    BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cysteine and serine proteases in colorectal carcinoma.
    Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteine and serine proteases in gastric cancer.
    Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
    Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
    Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R
    Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
    Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
    Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
    Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
    Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
    Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F
    Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
    Høgdall CK; Christensen IJ; Stephens RW; Sørensen S; Nørgaard-Pedersen B; Nielsen HJ
    APMIS; 2002 Sep; 110(9):630-8. PubMed ID: 12529016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
    Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
    Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of cathepsins B and L in primary human breast cancer.
    Foekens JA; Kos J; Peters HA; Krasovec M; Look MP; Cimerman N; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    J Clin Oncol; 1998 Mar; 16(3):1013-21. PubMed ID: 9508185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
    Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
    Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
    Schweiger A; Christensen IJ; Nielsen HJ; Sørensen S; Brünner N; Kos J
    Int J Biol Markers; 2004; 19(4):289-94. PubMed ID: 15646835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
    Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
    Papadopoulou S; Scorilas A; Yotis J; Arnogianaki N; Plataniotis G; Agnanti N; Talieri M
    Tumour Biol; 2002; 23(3):170-8. PubMed ID: 12218297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.